<SEC-DOCUMENT>0001125345-22-000092.txt : 20221017
<SEC-HEADER>0001125345-22-000092.hdr.sgml : 20221017
<ACCEPTANCE-DATETIME>20221017162257
ACCESSION NUMBER:		0001125345-22-000092
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20221017
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221017
DATE AS OF CHANGE:		20221017

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		221313952

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mgnx-20221017.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:ab8d6cd8-0de3-4c7e-b5d0-f1519c301ff2,g:fd996afc-e7d9-4acf-8b73-adbd7bdc812d,d:08f3f0785f2743dbac65529417d27f15--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20221017</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV80L2ZyYWc6ODJhZDc4YThjZTBkNGU3MjhmNjFmOTBmMjczYzBiYmIvdGFibGU6ZDk2OTYyMTMyNTRlNDRmMzk0M2IyYzlhMDI5YjkyNjcvdGFibGVyYW5nZTpkOTY5NjIxMzI1NGU0NGYzOTQzYjJjOWEwMjliOTI2N18yLTEtMS0xLTUzMzcz_6ee307ef-7b78-4874-a515-f77b5a6e13d1">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV80L2ZyYWc6ODJhZDc4YThjZTBkNGU3MjhmNjFmOTBmMjczYzBiYmIvdGFibGU6ZDk2OTYyMTMyNTRlNDRmMzk0M2IyYzlhMDI5YjkyNjcvdGFibGVyYW5nZTpkOTY5NjIxMzI1NGU0NGYzOTQzYjJjOWEwMjliOTI2N18zLTEtMS0xLTUzMzcz_3cbc4b01-e5f6-46b6-98af-89dc488e4721">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20221017.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-17</xbrli:startDate><xbrli:endDate>2022-10-17</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i08f3f0785f2743dbac65529417d27f15_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18xMDY_fefa74a1-d5c0-46c8-88e9-e35d225b9305">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported):&#160; <ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M181NDk3NTU4MTU2MTA_8432bac8-b946-4e8b-8a31-f185c90be900">October 17, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18yNjk_d3c4e439-7273-4ec6-8d10-56a15a371ae7">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Exact Name of Registrant as Specified in Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:33.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6MjdkNTMwZDdkYzM3NDUyZGFjZTZjNDNkM2U5N2I0OTMvdGFibGVyYW5nZToyN2Q1MzBkN2RjMzc0NTJkYWNlNmM0M2QzZTk3YjQ5M18wLTAtMS0xLTUzMzcz_69565fc5-fc7c-4ca4-a3b4-6afa7890041b">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6MjdkNTMwZDdkYzM3NDUyZGFjZTZjNDNkM2U5N2I0OTMvdGFibGVyYW5nZToyN2Q1MzBkN2RjMzc0NTJkYWNlNmM0M2QzZTk3YjQ5M18wLTEtMS0xLTUzMzcz_036c5228-f5b2-423e-9e95-3f27d050b931">001-36112</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6MjdkNTMwZDdkYzM3NDUyZGFjZTZjNDNkM2U5N2I0OTMvdGFibGVyYW5nZToyN2Q1MzBkN2RjMzc0NTJkYWNlNmM0M2QzZTk3YjQ5M18wLTItMS0xLTUzMzcz_888fe648-d93e-411d-b4a0-0628a74afd82">06-1591613</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;Identification No.)</span></div></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.426%"><tr><td style="width:1.0%"></td><td style="width:23.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:24.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6ZTZkZWJlNWY3ODVlNGViOThkZDY1MmIzZmU1ZTliYmIvdGFibGVyYW5nZTplNmRlYmU1Zjc4NWU0ZWI5OGRkNjUyYjNmZTVlOWJiYl8wLTAtMS0yLTUzMzcz_f4b70aaa-b512-4ea4-aff7-e85e20915e46">9704 Medical Center Drive</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6ZTZkZWJlNWY3ODVlNGViOThkZDY1MmIzZmU1ZTliYmIvdGFibGVyYW5nZTplNmRlYmU1Zjc4NWU0ZWI5OGRkNjUyYjNmZTVlOWJiYl8xLTAtMS0xLTUzMzcz_1504a37f-0690-4cb4-afd1-741ffc279dea">Rockville,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6ZTZkZWJlNWY3ODVlNGViOThkZDY1MmIzZmU1ZTliYmIvdGFibGVyYW5nZTplNmRlYmU1Zjc4NWU0ZWI5OGRkNjUyYjNmZTVlOWJiYl8xLTEtMS0xLTUzMzcz_95f8db6b-672d-4c45-915f-d4955dfe32e2">Maryland</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6ZTZkZWJlNWY3ODVlNGViOThkZDY1MmIzZmU1ZTliYmIvdGFibGVyYW5nZTplNmRlYmU1Zjc4NWU0ZWI5OGRkNjUyYjNmZTVlOWJiYl8xLTMtMS0xLTUzMzcz_90168d44-f9d4-4df2-8953-3acfbd7db9c7">20850</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code:&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18zODU_6592c983-551c-45f5-ad06-3a9bfdbf5f92">301</ix:nonNumeric>) <ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18zODk_753614ed-02e6-40ff-a953-607db36640c1">251-5172</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:34.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.051%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6MDcwNDlkZTYyZThjNDU3NmIzN2JjYTE2Y2M3MTdlMGIvdGFibGVyYW5nZTowNzA0OWRlNjJlOGM0NTc2YjM3YmNhMTZjYzcxN2UwYl8zLTAtMS0xLTUzMzcz_5ba1563e-fa8a-4bd5-b49d-ce9ac12af332">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6MDcwNDlkZTYyZThjNDU3NmIzN2JjYTE2Y2M3MTdlMGIvdGFibGVyYW5nZTowNzA0OWRlNjJlOGM0NTc2YjM3YmNhMTZjYzcxN2UwYl8zLTEtMS0xLTUzMzcz_1fb42962-6433-4f20-b0b4-19ce58ad13d5">MGNX</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6MDcwNDlkZTYyZThjNDU3NmIzN2JjYTE2Y2M3MTdlMGIvdGFibGVyYW5nZTowNzA0OWRlNjJlOGM0NTc2YjM3YmNhMTZjYzcxN2UwYl8zLTItMS0xLTUzMzcz_ff6be2f2-4e48-432b-9911-02f2669d6b5c">Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18xNjU1_9491ec7e-9387-4bf4-8703-a7dd31d3e1c1">&#9744;</ix:nonNumeric> Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18xNjU2_71c56794-9b95-475f-9fab-def27cc36f49">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18xNjU3_f7d429b0-251f-481e-8415-629204f2cd1c">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18xNjU4_b430f98a-5f83-4ca3-8a50-9db12eb3510b">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18xNjU0_dbe65cf3-5427-471c-83f9-1e203e08145a">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i08f3f0785f2743dbac65529417d27f15_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entry into a Material Definitive Agreement. </span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On October 14, 2022, MacroGenics, Inc. (the &#8220;Company&#8221;) and Gilead Sciences, Inc. (&#8220;Gilead&#8221;) entered into exclusive option and collaboration agreement (the &#8220;Agreement&#8221;) to develop MGD024, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">an investigational, bispecific antibody that binds CD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3 and CD3 using the Company&#8217;s DART&#174; platform,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> and two additional bispecific research programs. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The agreement grants Gilead the option to license</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> MGD024, a potential treatment for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As part of the Agreement, Gilead will pay the Company an upfront payment of $60 million and the Company will be eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones. The Company will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 and a flat royalty on worldwide net sales of products resulting from two research programs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company will be responsible for the ongoing Phase 1 study during which Gilead may elect to exercise its option to license the program at predefined decision points. The Phase 1 study will include a dose escalation segment and an expansion segment that is intended to evaluate MGD024 as monotherapy and in combination with other therapies across multiple indications.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Agreement will continue in full force and effect on a product-by-product and country-by-country basis until expiration of the last royalty term for a product in such country. No sooner than 18 months after the effective date of the Agreement, Gilead may terminate the Agreement for convenience either in its entirety, or on a product-by-product basis, with specified notice requirements which vary depending on whether said termination for convenience is before or after the option exercise.   In addition, Gilead may terminate the Agreement on a product-by-product basis for safety reasons and for other specified reasons with certain notice and other requirements. Either party may terminate the Agreement upon a material breach by the other party that remains uncured or upon certain bankruptcy events or for a force majeure event. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which will be filed in redacted form as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ending December 31, 2022.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.192%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Item 7.01</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Regulation FD Disclosure.</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On October 17, 2022, the Company and Gilead issued a joint press release announcing the Agreement (the &#8220;Press Release&#8221;). The full text of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this item of this report.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Forward-Looking Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These include statements about future expectations, plans and prospects for the Company, including statements about the Company&#8217;s strategy, future operations, clinical development of its therapeutic candidates, milestone, target nomination, option or royalty payments from the Company&#8217;s collaborators, the Company&#8217;s anticipated milestones and future expectations and plans and prospects for the Company. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company's views only as of the date hereof. The Company anticipates that subsequent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:15.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Statements and Exhibits</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.332%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d) Exhibits.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:15.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991gilead-macrogeni.htm">99.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991gilead-macrogeni.htm">Press Release dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991gilead-macrogeni.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991gilead-macrogeni.htm">October 17, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:48.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.841%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date: October 17, 2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MACROGENICS, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Senior Vice President and General Counsel</span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991gilead-macrogeni.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i02b1c9c2606546d48d38faa1b88178c3_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 99.1</font></div></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:58px;margin-bottom:5pt;vertical-align:text-bottom;width:179px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:68px;margin-bottom:5pt;vertical-align:text-bottom;width:126px"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Gilead Contacts&#58; &#160;&#160;&#160;&#160;MacroGenics Contact&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jacquie Ross, Investors&#160;&#160;&#160;&#160;Jim Karrels, Senior Vice President, CFO</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">investor_relations&#64;gilead.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">info&#64;macrogenics.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Marian Cutler, Media<br></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Marian.Cutler1&#64;gilead.com</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GILEAD  AND  MACROGENICS  ANNOUNCE  ONCOLOGY  COLLABORATION  TO  DEVELOP  BISPECIFIC  ANTIBODIES  </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Gilead Granted Exclusive Option to License MGD024, a Phase 1 CD123&#215;CD3 DART</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%"> Molecule with Potential to Treat Various Hematologic Malignancies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> &#8211;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Potential for Companies to Collaborate on Two Additional Future Research Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> &#8211;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Foster City, Calif., and Rockville, Md. October 17, 2022 &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Gilead Sciences, Inc. (Nasdaq&#58; GILD) and MacroGenics (NASDAQ&#58; MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">an investigational, bispecific antibody that binds CD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">12</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">3 and CD3 using MacroGenics&#8217; DART</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;platform,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> and two additional bispecific research programs. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The collaboration agreement grants Gilead the option to license</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> MGD024, a potential treatment for </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">A leader in the bispecific antibody space, MacroGenics has extensive experience applying its proprietary DART platform to develop novel therapeutics. MGD024 is a next</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">-generation, bispecific that incorporates a CD3 component that is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> designed to minimize cytokine-release syndrome (CRS), a potentially life-threatening toxicity, while increasing the magnitude of antitumor activity with a longer half-life to permit intermittent dosing. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8220;MacroGenics&#8217; bispecific expertise naturally complements Gilead&#8217;s portfolio strengths in immuno-oncology and our growing hematology franchise,&#8221; said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Development, Gilead Sciences. &#8220;We believe MGD024, with its potential to reduce CRS and permit intermittent dosing through a longer half-life, could translate to more patient-friendly dosing and enhanced clinical outcomes for people living with AML and MDS. This partnership is the latest in our efforts to develop and advance transformative new cancer therapies as we deepen our portfolio across oncology indications.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Scott Koenig, MD, PhD, President, and CEO, MacroGenics said, &#8220;Rapid advances over the last decade have made CD123 a very promising target in oncology research. Advancing our bispecific DART molecule, MGD024, through a strategic collaboration with the team at Gilead will accelerate our ability to drive further development of MGD024 to the potential benefit of people living with blood cancers.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">MacroGenics will be responsible for the ongoing Phase 1 study for MGD024 during which Gilead may elect to exercise its option to license the program at predefined decision points. The Phase 1 study will include a dose escalation segment and an expansion segment that is intended to evaluate MGD024 as monotherapy and in combination with other therapies across multiple indications.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%;text-decoration:underline">Financial Considerations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">As part of the agreement, Gilead will pay MacroGenics an upfront payment of $60 million and MacroGenics will be eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones. MacroGenics will also be eligible to receive tiered, double-digit royalties on worldwide net sales of MGD024 and a flat royalty on worldwide net sales of products under the two research programs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (SEC), Gilead no longer excludes acquired IPR&#38;D expenses from its non-GAAP financial measures and expects the transaction with MacroGenics to reduce Gilead&#8217;s GAAP and non-GAAP 2022 EPS by approximately $0.04.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%;text-decoration:underline">About&#8239;MacroGenics, Inc. </font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of&#160;MacroGenics'&#160;technology platforms and protein engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the company's website at&#160;www.macrogenics.com.&#160;MacroGenics, the&#160;MacroGenics&#160;logo, and DART are trademarks or registered trademarks of&#160;MacroGenics, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%;text-decoration:underline">About Gilead Sciences</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%;text-decoration:underline">Gilead Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties, and other factors, including the ability of the parties to complete the transaction in a timely manner or at all&#59; the possibility that various closing conditions for the transaction may not be satisfied or waived, including the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction&#59; the risk that Gilead may not realize the potential benefits of this collaboration with MacroGenics or its other investments in oncology&#59; difficulties or unanticipated expenses in connection with the collaboration and the potential effects on Gilead&#8217;s revenues and earnings&#59; Gilead&#8217;s ability to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">achieve its anticipated full year 2022 financial results&#59; the ability of the parties to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional trials, including those involving MGD024 or future research programs&#59; the ability of the parties to file applications for regulatory approval or receive regulatory approvals in a timely manner or at all, including those involving MGD024 or future research programs, and the risk that any such approvals may be subject to significant limitations on use&#59; the possibility that the parties may make a strategic decision to terminate the collaborations, including the development of MGD024 or future research programs, at any time&#59; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%;text-decoration:underline">MacroGenics Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Any statements in this press release about future expectations, plans and prospects for MacroGenics, including statements about the MacroGenics&#8217; strategy, future operations, clinical development of MGD024, including initiation and enrollment in clinical trials for MGD024, the consummation of the transactions discussed in this press release, milestone or option payments from Gilead and other statements containing the words &#8220;subject to&#8221;, &#34;believe&#34;, &#8220;anticipate&#8221;, &#8220;plan&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;potential,&#8221; &#8220;project&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;would&#8221;, &#8220;could&#8221;, &#8220;can&#8221;, the negatives thereof, variations thereon and similar expressions constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including&#58; risks that MGD024 may not provide a significant clinical benefit to patients with certain blood cancers&#59; the uncertainties inherent in the initiation and enrollment of clinical trials&#59; the availability of financing to fund the development of MGD024 and MacroGenics&#8217; other product candidates&#59; availability and timing of data from ongoing clinical trials&#59; expectations for developing further programs under the collaboration agreement with Gilead&#59; the possibility that the parties may make a strategic decision to terminate the collaborations, including the development of MGD024 or future research programs, at any time&#59; expectations for the timing and steps required in the regulatory review process for MGD024&#59; expectations for regulatory approvals&#59; expectations of milestone payments&#59; the impact of competitive products&#59; economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict&#59; public health crises such as the COVID-19 pandemic&#59; and other risks described in the MacroGenics&#8217; filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent MacroGenics&#8217; views only as of the date hereof. MacroGenics anticipates that subsequent events and developments will cause MacroGenics&#8217; views to change. However, while MacroGenics may elect to update these forward-looking statements at some point in the future, MacroGenics specifically disclaims </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing MacroGenics&#8217; views as of any date subsequent to the date hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">###</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Gilead and the Gilead logo are trademarks of</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Gilead Sciences, Inc., or its related companies. </font></div><div><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">For more information about Gilead, please visit the company&#8217;s website at www.gilead.com, follow Gilead on Twitter (&#64;GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mgnx-20221017.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ab8d6cd8-0de3-4c7e-b5d0-f1519c301ff2,g:fd996afc-e7d9-4acf-8b73-adbd7bdc812d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20221017" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20221017">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20221017_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20221017_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://macrogenics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mgnx-20221017_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ab8d6cd8-0de3-4c7e-b5d0-f1519c301ff2,g:fd996afc-e7d9-4acf-8b73-adbd7bdc812d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_5cc841e1-8c5c-4e53-bccf-dfe069a0a07a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_eccc775f-4ed3-4e2a-8879-a9b21a3d9cf8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a9685fe9-3345-4058-b89c-a5d6aefaa7ad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c0816f59-d7f2-4b0e-a19f-59a9c551fbe8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a03ef128-9d76-4328-92d0-415739d61159_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_95032caf-b411-47d7-8af0-b15b4c685dcf_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_ee3cb810-0e0f-410b-a7d9-7ec589e0ae38_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fc172390-75cf-4523-ad08-b763353eb76b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_10c4046e-a51b-496b-b1c1-c3fb7f9258b8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ecd8cdc0-65e6-499c-9428-8b2741b831bd_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ef797fd2-2c3a-42bf-b863-16506f2071cd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_4941e1af-2ca9-4264-ba2d-f62c31220077_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_17081939-839a-4620-98fc-1c3fb052e942_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d6cfdf88-ffba-4dbc-9154-9d4e26384188_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7f168365-5952-4814-8091-42023ca0d2bd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_21308759-6718-4909-9b23-009ed3bd69e7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1fa7d92a-0882-4af9-8231-dd8e029a3d0e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2d902c53-0015-44ad-9527-4d9060cf0026_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e9fea570-9f84-4eb0-9728-a6482fac19f2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2d35d732-1830-4eec-b4e9-6be982f3a760_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f245c9e7-3ac6-4f30-b9c1-e224af556e36_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_f2158284-196b-448b-a05a-93dc32d0767d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mgnx-20221017_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ab8d6cd8-0de3-4c7e-b5d0-f1519c301ff2,g:fd996afc-e7d9-4acf-8b73-adbd7bdc812d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/Cover" xlink:type="simple" xlink:href="mgnx-20221017.xsd#Cover"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4247cbcd-7b07-4e19-a73d-66da410a30b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_DocumentType_4247cbcd-7b07-4e19-a73d-66da410a30b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0a97cd20-b0e0-40e1-b96e-a4529aded39c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_DocumentPeriodEndDate_0a97cd20-b0e0-40e1-b96e-a4529aded39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2182502f-2c0e-44e0-8d31-484da63575b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_EntityRegistrantName_2182502f-2c0e-44e0-8d31-484da63575b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_894d53cd-c116-40ba-8d62-df4c6b322fd4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_894d53cd-c116-40ba-8d62-df4c6b322fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7fa04194-0ff4-4a88-a375-d48ad3f6b072" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_EntityFileNumber_7fa04194-0ff4-4a88-a375-d48ad3f6b072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_933aedc0-6036-418e-adc8-cbd5a85592e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_EntityTaxIdentificationNumber_933aedc0-6036-418e-adc8-cbd5a85592e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6b66c0f4-0646-4465-ad5d-a7cd3bb7aa10" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_EntityAddressAddressLine1_6b66c0f4-0646-4465-ad5d-a7cd3bb7aa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f80a33ee-9ab9-4182-a33f-5c4d70d73074" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_EntityAddressCityOrTown_f80a33ee-9ab9-4182-a33f-5c4d70d73074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_31bfe219-7751-41c0-97b8-2da10376071e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_EntityAddressStateOrProvince_31bfe219-7751-41c0-97b8-2da10376071e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3c884fee-08f7-48c5-8d6e-c2bc67a94203" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_EntityAddressPostalZipCode_3c884fee-08f7-48c5-8d6e-c2bc67a94203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2f72ef80-4133-46c7-ae15-e720a603d027" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_CityAreaCode_2f72ef80-4133-46c7-ae15-e720a603d027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c84dde1f-7d16-408d-b121-f652f52217d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_LocalPhoneNumber_c84dde1f-7d16-408d-b121-f652f52217d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c190e1f8-15b6-4cda-be51-ecf1b809fcd1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_Security12bTitle_c190e1f8-15b6-4cda-be51-ecf1b809fcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1239a6c5-8235-4c37-a14e-6d5470d10350" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_TradingSymbol_1239a6c5-8235-4c37-a14e-6d5470d10350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3a20fe91-0f76-48a3-ad38-76a3b6a182ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_SecurityExchangeName_3a20fe91-0f76-48a3-ad38-76a3b6a182ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_865d0af6-5fd8-43c9-90cb-620d02d7ceec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_WrittenCommunications_865d0af6-5fd8-43c9-90cb-620d02d7ceec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_afdc0a66-a0fd-40c7-bddd-6a08965aab2f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_SolicitingMaterial_afdc0a66-a0fd-40c7-bddd-6a08965aab2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_6d066bb5-670d-4f2c-b025-f1bae11ebbc7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_PreCommencementTenderOffer_6d066bb5-670d-4f2c-b025-f1bae11ebbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_107f5a0d-b71a-4d9c-9767-64abf072016a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_107f5a0d-b71a-4d9c-9767-64abf072016a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a391c302-e983-44a5-88f8-f430ec6751c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_EntityEmergingGrowthCompany_a391c302-e983-44a5-88f8-f430ec6751c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2250b61e-d07d-48c0-ac7a-6378d060e310" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_EntityCentralIndexKey_2250b61e-d07d-48c0-ac7a-6378d060e310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_eed47d99-2ae4-4c71-85d2-980359681fb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff22c427-de53-4716-8ab1-02b2a46719f9" xlink:to="loc_dei_AmendmentFlag_eed47d99-2ae4-4c71-85d2-980359681fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c8ee15e1-daf4-489a-9e4f-25a38edf797f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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MSZCHZNJFD]JAHJ**W5Q1K*33B0%;D)M!%^ J%94V#@)$_\  G=15-F_]CJH
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M#.7*JQ9O<_GKZ0V[PNA,Q:.^OM$O()"M<UPL7KHJ.B:VJ:F9VLHQJ#\ZG7C
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M!]06QPT]*@(W;NWHZ'#0$/8UW-6?MKZ%F\JT(_$:O6XF7H0EP8;@-;/.QG,
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2%7>;$,)N     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "? 2@# 2(  A$! Q$!_\0
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M_:&U3Q%K$/[,/PFGDN+Z^N(X-=:TQNED<@1V2M[D@OC_ &4)_P!8M>U?LO\
M[/FD_L]?#B+P\!!/K%YMGUW4(5/[Z;!PBD\^6@)5>F?F; +D55K1U ](HHHJ
M0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KR']L']I.T_9_^'[1Z/<JWB35XWBT6'RP
MWDXX:X;/&$R, YW,0,$!B/0/B;\1_#/PF\#ZAX_\6W+1V.GP[W6-=SRL3A(T
M'=F8A1D@9.20,D?(/P#^'OBG]M?XZWWQP^*D;-X=TV\4?8Y%W12%?FBL$X"^
M6@(:3C+;N1F4L*BNK ] _8&_9RO=)M6_:*^(Y>YUK6XVET<7>7DBADR7NF9N
M3)*"<'KL).3YA ^G.E"C:-H%%)NX!1112 **** "F3O-''OAB\PC^#=@D>WO
M_GBGT4 0V=];W\7G6[="0RL,,K#J".QJ:LO6[*[M'_MO14_?K_KH1TG7T_WA
MV/7MS5G1=9M-<L5O;-^#PR]T/H: +=%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '$_'[XXZ#^S]X#_P"$[\0:/>7T;WD=K#;V:C)D
M968%B>%7"'GUP.]:/PF^+'@SXT>"K;QUX'U'SK6X^66%\"6UF !:&5<G:ZY'
ML00P)5@3I^,/"'AOQ]X9O/!WB_2(;[3=0A,5U:S+PPZ@CN&! 8,,%6 (((!K
MXIE3Q_\ \$[OCMYD37.J>$-:Z X'VVW4]#_"+B+=UX!#=E<@4ES ?=%%9G@W
MQAX;\?\ A>R\9>$-6COM-U"'S;6ZAZ,,X((/*L""I4@%2"" 016G4@%([K&A
M=V"JHR6/:EKY;_;[_:*U"V5?V;OAL+BXUC5O+CUIK/+2".7&RS15^8O+D;A_
M<8+AO,.&ES <'\:_'?BC]N;X]V/P>^&-Q,GAK2YF(NMI:)@IQ+?N!_" =D88
M\[@,J92H^QOAWX \-_"[P7I_@/PE:&&QTVW$4.[&]SU:1R  79B68X&23P*X
M/]DC]G*Q_9\^'BVVH(LGB#50LVN7'!V-CY8$(_@3)YR=S%FZ$*OJU.3Z( HH
MHJ0"BBB@ HHHH **** "N3\1K<>"]:7Q-8*S6=PVV^A7&,^OX]1[]^<5UE5]
M4TZVU;3YM.O$W1S1E6]O<>XZT 26=W;WUK'>6DH>.1 T;#N#4E<+\-M;NM$U
MZZ^'VL-\\<C-:GGG') ]B/G'X^M=U0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5S?Q8^%7@[XS>"+OP+XVTX36MPNZ&9<>;:S ';-&W
M\+KGZ$$J059@>DHH ^'?A7X^\=_L&?&BY^%OQ-DFN/"NI3!VN(XV,>PG:M]$
MO)S@;9$&20N/F*K7VWIFIZ?K.G6^KZ1>PW5K=0K-;7%O('CEC895U8<$$$$$
M<$&N*_:$^ 'A#]H7P.WA;Q$/L]Y QDTG5HXPTEE-CKCC<C8 9,@, .C*K+\Q
M_LZ?M#^)?V1O%VJ? CX^1W2Z39M(]JT:M,;.3!<>5W:&7J,<!F#8&YS5_$!]
M%?M5_M#Z=^SU\.6UB$13ZWJ):WT.RD8?-)CF9AG)CCR"<=257(W9'D/[!/[.
MNI7UW)^TO\4EN+C4M0DDET-;TDN^\G?>OGDL^6"$]BS\[D8<3\*_!_BS]O3]
MH&\^)_Q"L)(/"NER(LMLDQV+&IS%8HW!);EI&4#JQ^0N@K[?M[>"TMX[6U@2
M.*- D<<:A510,  #H .U)^ZK /HHHJ0"BBB@ HHHH **** "BBB@ HHHH \U
M^.%E<Z#J>G^.-,^6195CD;C D7YD..^0&![845WWA_6+;Q!HEKK=F?W=U"L@
M7=G;GJI]P<@^XK'^+>DKK'P[U2(G:T%L;A&VYP8_GX^H!'XUS/[-'BAM7\+W
MF@2R,S:;<!HQM&%CDR0/^^A(?QI] /2J***0!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %>+_MA?M%^,/@)9:#%X-TNPFN-8DN3)-J".ZQK$(N
M JLO),O4G@+T.<CVBOE?_@IA_P R3_W$O_;6OSWQ5S7,,EX!QF,P-1TZL?9V
MDMUS581=O5-KYGUG ^!PN9<48?#XF"G"7-=/9VA)K\4F97PW_P""@WQ"O/&V
MFZ;\0M*T-='NKM(;ZXMX)8GMT8[?-W&1AA<[B"IR 0,=:]K_ &E?V5_!?[2&
MCV_V^\_LG6K$@66M06PD81YRT,BY7S$Y) W JW(."ZM\@_$+X>G3O@AX!^)M
ME;-Y6I6U]97S+%\JS17L[(6;^\R,0!Z0U]H?LO\ Q('Q1^">B^(+BZ\V^@M_
ML>I9DW-Y\7R%F_VG7;)])!7P7@[Q=G^*S*OD^=UW4J.G2KTI2W<*D(R:OULI
MP:71\WG;ZCQ R'*\/A*689;34(*<Z4TMN:,FD[=-8R_ Y/XG^)O"_P"Q'\"-
M.\/?#;28)+AK@6^GPWTA9IY2"\MS-M*L_3G;@ NB@*H 'B^F_P#!1'XSP:A!
M+JN@:#<6JRJ;B&*UEC>2//S!6\T[3CH2" >QZ5'^VYXQU#XJ?'RS^&OAL_:1
MI/EZ?:0QRJRR7LS*7P1T.3'&0>C1GI7"_M.^$[#P'\:-2\&:6Q:WTNQTVVCD
M90&DV6%N-YQQECR?<FO@O$?Q XN>>8S%93BY4L+AJM.@E&UI5'&I*3>FMI4Y
M)[JW+WU^HX1X5R'^S</0Q]",ZU:$JMWNHIP27E=23Z:W['Z(KD#FER.F:*^$
M?VK/%.O?&S]HR\\+^%X+B^&FS?V5I=G&O+21Y\T@9QS)YGS=U5<]*_H+C[C:
MGP/E=/$^P=>I4FH0IJ7*Y-IMZ\LGI:VD7=M+J?E/"W#<^)L=.C[3V<(1<I3:
MNDE9=UOZK1-]#[NS17QK_P $\OB3+H?Q&OOAM>W3?9=<M#+9QLQ(%S""V .B
M[H_,)/?RU'85]6_$SQ[I'PO\!ZIX]US)M]-MC(8UZRN2%2,<'!9RJ@] 6YXJ
MN#N.LOXLX5>=RBJ,8<_M$Y<RAR:N\K*ZY;2V6C%Q!PSBLCSM9:G[1RY>1I6Y
MN;165W]J\=WJC=R/6FK+&XW)(K<D<'N#@BOS]DUSXZ_M@?$5?#_]I274LK--
M'9><T=CIT.[!<J,[57< 6PSMP/F8@'K-5_8I_:.^%4"^-O!6N6MY>6@W;?#]
M]*ETHP22H9$WC QM!+-G 4U\'A?&+-LVC4Q659)6KX2#:=12M)VW:@H2NTM;
M*3Z7:/IZWA_@<"X4,=F5.E7DK\CC=:[7ES*R;ZN/I<^V-P]:,U\W_P#!0._U
MN'X-^&8KV9H9YM41KZ.%\*9! ^1QU )->,?!C]E7XD?''P;-XS\,>*]-MH8K
MY[7R;^XF5BZJC9^1&&/G'^%>KG_BAF66\5RR++LKEB:BA&>E10=FDW[KA+:Z
MOKOT.'*^"\'C,C69XO&JC!R<=8.2NG;=26]NQ][Y'3-%? /P]^-?Q=_9O^)A
MT#6=<O);/3=0:VUG1;BY:6%T#8<Q@G"M@95UQGC.5)!^L/VIOCTOP)^'BZAI
MHBDUK4Y3;Z3#)@@$#+S%<\J@(]?F= >"37?PWXJY)G>1XS,,33EAWA/XL):N
M-[I6>EW)IQ2:3YE:VS?-F_ ^99;F6'PE&:JK$?PY+1.UKWWM9--N[5M;GICR
M1QJ7=U55&69CTHCFBF02Q2JRMRK*V0:^"/AW\'/CC^UMJU[XJOO$AFAMY"D^
MK:U<N8Q(<-Y,2J#R P.U0%48Z94%/BK^SO\ &+]F)K3QK%XC06\D_D0ZMH=Y
M)')#(5)"MPK+N ;ID<8)!(!^5?C)GDLM>;4\BJ/!)_Q?:)/EO;FY>1Z?]O.-
M_M'M_P#$/<L6,6 EF<%B?Y.1VO:]N;F_2_D??+HDJ-'(@96&&5AP1Z5\Q>"/
MBAX>_9MT/Q)\8_BOJWV'P_8*VG*BX:>_O]X*001Y_>/M5^X !+,0JNR]]^Q]
M^T#J7QP\$75KXJ"'6]$DCBO9HDVK<QN#Y<N!P&)1PP'&5R,!@H^$_P#@K-\4
M[GQ+^T<?A!IT36^C^#;5?+M58%);R[5;J>?@9!(EC3:2<&-B,;B*^XS;Q P%
M/@N&>Y?[ZK65--?:=[J276'+*Z3U<;)ZW/(R'@O%8[BJ64XOW?9WE-K^56MR
M_P"+FC9VT3O;2QO?%#_@L3\?_%^L2Z9\&_!VD^'K.9Q'8M<6[7U^S9P#EB(L
MMQA!&<'C<W6LC_AXM_P43^$%Q#J'Q1MI)(;C_CWA\6>"ULXY?]TPI S?@U?9
M7[!/[(W@[]G/X0Z3K5WX?A;QEK&FQW&O:I<6H6XA:4!_LBDDE$CRJ$*0'9-Y
M R ON]W96E_:R6-]:QS0S1E)H9D#*ZD8*D'@@^E>/@>$^-,RPL<9C,VJ4ZLD
MGR13Y8WULTI13?=)63[GMXSBK@_+L5+"83*Z=2E%M<TG[TK:73<9-+LV[M=C
MPO\ 8/\ VT$_;!\%ZI=ZKX5CTC7/#\EO%JT-M<&2WF\U&*S1[AN0,T<H\LEB
MH4?.V3CWBN1^&7P)^$7P9OM8U#X6> ;#0FUZXCFU2/3D,<<C(I5-L>=D8 )^
M5 JY8G&237Y-_M52>*?&W[9_C7P__P )!</<7GCRYL+66[NG98U^T&&)<\D(
MB[5  X50 , "O7S?B7,^"\CPSS"*Q->4G!N+Y$]VG\+UM9-66M]>_EY3PYEO
M&.=XE8"3P]&,5)*2YVMDU\2TO=IW>EM.W[)49K\U/^'-W[4Q&/\ A:W@W_P9
M7W_R-7T]^U+HGBKX._\ !-*_\'-KICU70?!.E:5>7VG3NJR,AMK>;8Q"L4<;
MQR 2K<CDBN_ \39Q4PN)Q&.R^5"-*#FKS4N;E3;BO=5MM]3AQO#>4T\5AZ&!
MQ\:\JLU!V@UR\S23?O.^^VA]&YHS7X2^'O%7C?P=JECXU\,Z[?6-U9WN^POX
M)R&CFCVMQSU&Y>#P<]Z_8CX6_'&P_:!_91C^,6C$6\VH^&[EKR&%B/LMY'&Z
M31CG("R*VTGDKM;O7#PCX@8;BFI6I.C[*=./,ES<W-'JT^6-K.W3JF=G%G >
M(X8C1J*M[6$Y<K?+R\LNB:YI;J_7HSU+(]:,CUK\R_\ @B_++_PT[X@B\UMK
M^!+EF7<<,PO;/!/N,G\SZU1_X+&R2/\ M76,;R,5C\'VFQ2QPO[^XZ>E<TO$
M3EX16>?5MY\G)S_CS<GX<OS.F/A_?BQY+]9VAS\_)^'+S?CS?(_4('/2C(]:
M\F^%/Q*T/X7_ +$/A+XJ>-KV3['I/PSTR^OI#(#)-ML(CM4N0&D=L*H)^9F
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M,&C^*M%BC>_L[:8M#=PM\OVB$-\RJ'RK(2VS<GSMNX\%_:H_X*G_ +/?QJ^
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MC'F8&#^S]\.M:_:9_:!@LO$TK7D=Y>2:IXFN?N[X0^^7.S;MWLPC&W&TR @
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M, (6C_9(_8+N[JXM?B3\>=&\NWCVRZ=X9N5^:4]0]RO91_SQ/)/#@ %&^Q
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3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139852249545312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 17, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 17,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>mgnx-20221017_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20221017.xsd" xlink:type="simple"/>
    <context id="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2022-10-17</startDate>
            <endDate>2022-10-17</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV80L2ZyYWc6ODJhZDc4YThjZTBkNGU3MjhmNjFmOTBmMjczYzBiYmIvdGFibGU6ZDk2OTYyMTMyNTRlNDRmMzk0M2IyYzlhMDI5YjkyNjcvdGFibGVyYW5nZTpkOTY5NjIxMzI1NGU0NGYzOTQzYjJjOWEwMjliOTI2N18yLTEtMS0xLTUzMzcz_6ee307ef-7b78-4874-a515-f77b5a6e13d1">0001125345</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV80L2ZyYWc6ODJhZDc4YThjZTBkNGU3MjhmNjFmOTBmMjczYzBiYmIvdGFibGU6ZDk2OTYyMTMyNTRlNDRmMzk0M2IyYzlhMDI5YjkyNjcvdGFibGVyYW5nZTpkOTY5NjIxMzI1NGU0NGYzOTQzYjJjOWEwMjliOTI2N18zLTEtMS0xLTUzMzcz_3cbc4b01-e5f6-46b6-98af-89dc488e4721">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18xMDY_fefa74a1-d5c0-46c8-88e9-e35d225b9305">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M181NDk3NTU4MTU2MTA_8432bac8-b946-4e8b-8a31-f185c90be900">2022-10-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18yNjk_d3c4e439-7273-4ec6-8d10-56a15a371ae7">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6MjdkNTMwZDdkYzM3NDUyZGFjZTZjNDNkM2U5N2I0OTMvdGFibGVyYW5nZToyN2Q1MzBkN2RjMzc0NTJkYWNlNmM0M2QzZTk3YjQ5M18wLTAtMS0xLTUzMzcz_69565fc5-fc7c-4ca4-a3b4-6afa7890041b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6MjdkNTMwZDdkYzM3NDUyZGFjZTZjNDNkM2U5N2I0OTMvdGFibGVyYW5nZToyN2Q1MzBkN2RjMzc0NTJkYWNlNmM0M2QzZTk3YjQ5M18wLTEtMS0xLTUzMzcz_036c5228-f5b2-423e-9e95-3f27d050b931">001-36112</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6MjdkNTMwZDdkYzM3NDUyZGFjZTZjNDNkM2U5N2I0OTMvdGFibGVyYW5nZToyN2Q1MzBkN2RjMzc0NTJkYWNlNmM0M2QzZTk3YjQ5M18wLTItMS0xLTUzMzcz_888fe648-d93e-411d-b4a0-0628a74afd82">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6ZTZkZWJlNWY3ODVlNGViOThkZDY1MmIzZmU1ZTliYmIvdGFibGVyYW5nZTplNmRlYmU1Zjc4NWU0ZWI5OGRkNjUyYjNmZTVlOWJiYl8wLTAtMS0yLTUzMzcz_f4b70aaa-b512-4ea4-aff7-e85e20915e46">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6ZTZkZWJlNWY3ODVlNGViOThkZDY1MmIzZmU1ZTliYmIvdGFibGVyYW5nZTplNmRlYmU1Zjc4NWU0ZWI5OGRkNjUyYjNmZTVlOWJiYl8xLTAtMS0xLTUzMzcz_1504a37f-0690-4cb4-afd1-741ffc279dea">Rockville,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6ZTZkZWJlNWY3ODVlNGViOThkZDY1MmIzZmU1ZTliYmIvdGFibGVyYW5nZTplNmRlYmU1Zjc4NWU0ZWI5OGRkNjUyYjNmZTVlOWJiYl8xLTEtMS0xLTUzMzcz_95f8db6b-672d-4c45-915f-d4955dfe32e2">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6ZTZkZWJlNWY3ODVlNGViOThkZDY1MmIzZmU1ZTliYmIvdGFibGVyYW5nZTplNmRlYmU1Zjc4NWU0ZWI5OGRkNjUyYjNmZTVlOWJiYl8xLTMtMS0xLTUzMzcz_90168d44-f9d4-4df2-8953-3acfbd7db9c7">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18zODU_6592c983-551c-45f5-ad06-3a9bfdbf5f92">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18zODk_753614ed-02e6-40ff-a953-607db36640c1">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6MDcwNDlkZTYyZThjNDU3NmIzN2JjYTE2Y2M3MTdlMGIvdGFibGVyYW5nZTowNzA0OWRlNjJlOGM0NTc2YjM3YmNhMTZjYzcxN2UwYl8zLTAtMS0xLTUzMzcz_5ba1563e-fa8a-4bd5-b49d-ce9ac12af332">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6MDcwNDlkZTYyZThjNDU3NmIzN2JjYTE2Y2M3MTdlMGIvdGFibGVyYW5nZTowNzA0OWRlNjJlOGM0NTc2YjM3YmNhMTZjYzcxN2UwYl8zLTEtMS0xLTUzMzcz_1fb42962-6433-4f20-b0b4-19ce58ad13d5">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGFibGU6MDcwNDlkZTYyZThjNDU3NmIzN2JjYTE2Y2M3MTdlMGIvdGFibGVyYW5nZTowNzA0OWRlNjJlOGM0NTc2YjM3YmNhMTZjYzcxN2UwYl8zLTItMS0xLTUzMzcz_ff6be2f2-4e48-432b-9911-02f2669d6b5c">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18xNjU1_9491ec7e-9387-4bf4-8703-a7dd31d3e1c1">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18xNjU2_71c56794-9b95-475f-9fab-def27cc36f49">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18xNjU3_f7d429b0-251f-481e-8415-629204f2cd1c">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18xNjU4_b430f98a-5f83-4ca3-8a50-9db12eb3510b">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4ZjNmMDc4NWYyNzQzZGJhYzY1NTI5NDE3ZDI3ZjE1L3NlYzowOGYzZjA3ODVmMjc0M2RiYWM2NTUyOTQxN2QyN2YxNV8xL2ZyYWc6MzUxNzAyNjQ5ZmQ1NDMyZGIyYWY3MGJlMTAzZGM0NDMvdGV4dHJlZ2lvbjozNTE3MDI2NDlmZDU0MzJkYjJhZjcwYmUxMDNkYzQ0M18xNjU0_dbe65cf3-5427-471c-83f9-1e203e08145a">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4ON^0YV/!\]BLS7V@3OH)6S#E]S\D2PTM-Q")10QEZE0DFB^[CM#>G?OMVQ
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MS@Z2>W*>M&?S&;-I24G$UR#D77?!M?7AN'MH&)7D1\R5,G!@S6^WG,'<LA_
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ W()159>*NQS
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M4$L! A0#%     @ W()150=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #<@E%5"K=NO.X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" #<@E%5F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( -R"456L*"5O1@0  ( 0   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #<@E%5GZ ;\+$"  #B#   #0              @ &)#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( -R"4567BKL<P    !,"   +              "
M 64/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( -R"456JQ"(6,P$  "("   /
M              "  4X0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #<
M@E%5)!Z;HJT   #X 0  &@              @ &N$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #<@E%599!YDAD!  #/ P  $P
M            @ &3$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"  #=$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mgnx-20221017.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mgnx-20221017.htm">mgnx-20221017.htm</File>
    <File>exhibit991gilead-macrogeni.htm</File>
    <File>mgnx-20221017.xsd</File>
    <File>mgnx-20221017_lab.xml</File>
    <File>mgnx-20221017_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20221017.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "mgnx-20221017.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20221017_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20221017_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20221017.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20221017",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221017.htm",
      "contextRef": "if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://macrogenics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221017.htm",
      "contextRef": "if69b54f37c0243eeb03fadc2ddd4f94a_D20221017-20221017",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001125345-22-000092-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-22-000092-xbrl.zip
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M2#S,1:]2V5AR%!95.S-E$;$?(^>=*X.S@>5,Z %>/#R@C_*.+GOB"J+%_+8
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MGV-;S9S+D>H.X$6ONW((^-J3R8V<NK4_U*WSB7<^1&+:-B+6M8$B/0>#<GH
MS2 PY>@M&QE2D:J^X\ OIGPW:%E<6E:AL4;@&I0WE5,!Q8TX]Z4^*AN1!R4O
MLA ,>A7U\2ZI?P[7 B4EY@2+A4EB=(X5%([ 6\VM@U?N@R!P8_(38,L.7L$;
MEU,CM@D&;\K:Y=1EUKH1F")[KBSV;$U-9%*2R84- LE3DQD/[=YW QS@<@8Z
M:]DP#V@[ (_R:9D4.F>NUJ#\MPSORY+)MY7@WV@N10&>#DGWXD#YW5<0VWDF
M07!*2ESG0#HS&)[#%MK&!CTL\Z&E]>)6!=G?/=M F) D52YYF7F"F8W8-IF
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MEOK:T )!:NK_G;O$+H[MIW3.NY-%L76:.B/YQ5"L#/710)DJ&ZV1O24@O)^
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MI7Y@@_/P#E [6X; B;@G91^A/#@-DX]],.^UD%/],S(/K=\TA:0L.Y70$!"
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MYPF/LI#GO93=?*9I94NW-CZ6R\K&9[<-J]IE65;O?5B$UMC\>''8/8&)#!N
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M/0B!>?+F%Y#M#0@"<2,H;V]N<L#= O_G5J5P76GQ6T)2'O!1+PHY"44N:Y<
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MW;?PFY[)'O >GKR%_R#6"O;_'U!+ P04    " #<@E%59'&<)&L"  !K!P
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MB]<L(2+B@@ HI \"'DN0A ("A4)$N0^14OCEU6LE*(V8XD#&@H* <05($ON
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M0+"'B1Y!P&9UX "PQ[%=\>]KW%WXEP4SQ:Z+AWF2SZ8<$A2ID (1*PR"!$K
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MCW["_4AGV\=PJKW;>?8N)]DWG\2YOCI]L?XD7?XK[=,7_P-02P,$%     @
MW()151+-/%S+!@  HC$  !4   !M9VYX+3(P,C(Q,#$W7W!R92YX;6S5FEEO
MW,@1Q]_]*2:3U[2F+_8A6%HH6CL0HET+MA9>Y(7HHWI$F$,*)&5)WSY%2O):
ME\.( XA^F8/39%7_ZS?%KF*__>5J4RZ^0M,6=;6W9#MTN8 JU+&HUGO+/T[?
M$[/\9?_-F[=_(^3/?WX\7OQ:AXL-5-WBL '705Q<%MW9XG.$]LLB-?5F\;EN
MOA1?'2'[PTF']?EU4ZS/N@6GG#_\M=EUWD05HB$T@B R:" ^BY0DEC$;!&4I
M\7^L=U.T5KD4".AHB70A$>.U("[ZJ'T,AO$X7+0LJB^[_8MW+2QP<E4[?-U;
MGG7=^>YJ=7EYN7/EFW*G;M8K3JE8W8U>W@Z_>C3^4@RCF;5V-?SZ;6A;/#40
M+\M6?_YV_"F<P<:1HFH[5X7>0%OLML/!XSJX;M#\?_JU>'9$_XW<#2/](<(X
M$6SGJHW+_3>+Q8T<35W"1TB+_OV/CT??3&Y<:.HU5$5H=T*]6?6_KPYKI $]
M'<[LKL]A;]D6F_,2[HZ=-9#VEIMU=47ZD#+*=&_O[S<GKOXR>]Y BZ0,TSS&
M [?G]U;^;Q?@JH,JPLVL[@R4=;@WJ.PUK;^=63H/Y7 TCU#DPU4/?-LU+G0Y
M8L6#Y)I$R) [S10QSC-"N>=.*LULLO=GW'O<HLM#"%H(.^OZZPHOO.I5Z#\,
M<@Q2/#)W(\O+_+[[QYWBV%QRJ8,/D6A/-9' +'%:1*)4=))1)Z@7D]S^WMI]
MK[\/YT$3%G43H<&4<6?.->%>:!_C>CMB=>X:O! )9T49[\[N<\<V8M756U#N
M)BSH[G*!LT[0-!"/;Z+R[.2&F7682&$8N8V(GT!3U/%=%7_%3)M39W6(G!)/
M@1))@1%O%1 G,VX=_C>$#5L)_3VSHQC@\V?@Y5J^,@SOJJ[HKC_"NNB5J+K?
MW09RS@S/*$^$!PI$2IR$B8(1:61T2F0Z\VP2"T]9'86"F"\*DY6<!0E'N#IK
MSNMF$/X3Z@^']475-=>'=83<6!DS@5DN,)1%4N]P.HJ3F&107G">HMP"&#]T
M8A0G<NZ<;$_G66#SOBCA]XN-AR;7R5')K"0T)8EK:6.($SHC41H715)X?^1;
M8.0OBZ. R.8.Q L5G$7T3]W5442MBE3<E!VW$[%".(B!$D4%8LP,W@*QF"+!
MQ\R9++,<MI$NGC$_B@LU=RZVH>TL(#F($4/0WKYAQ08L5UZI0!%RJB1.0JH,
M)Y%%7#J'*+S7SC&Z!4">,#T*#CUW.*9J.B<P#O'CA^:TOJSR9+!@$@#$.F][
MMCDF0)%(%F34-&I!]3;RQB/#HZ P/PD4+]1S3D@,ZZ(/S4E3?RVJ +E@/@''
MTEKK#-?0#+.?U=X0'I%IH175#+;'Q0/KH^"P/PD<4Y2=$R$G==NY\C_%^;!L
M%L$8F9!S:I+&&BMD_;(92. ^*.VLY'1:^^IYV^.:6?0GP>/ELKXR''W2.VC
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M8W)O9V5N:2YH=&U02P$"% ,4    " #<@E%5CU&7XZD;  !ZJ   $0
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7;%!+!08     !0 % % !  !-1      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
